Literature DB >> 581329

Herpes zoster at the NIH: a 20 year experience.

M H Mazur, R Dolin.   

Abstract

One hundred and seven cases of herpes zoster in a hospitalized population with a variety of illnesses during a 20 year period were reviewed. Zoster occurred throughout the year, without seasonal predominance, and was most frequent in lymphoproliferative malignancy. In the majority, lesions were confined to the skin in one or more adjacent dermatomes (localized zoster) and were most frequent in the thoracic region. In 15 per cent of the cases, cutaneous dissemination of the lesions developed; this occurred four to 11 days after the onset of dermatomal lesions, and in one-third of these there was central nervous system involvement. Dissemination of zoster, however, directly resulted in only one death. Predisposing factors for zoster included local irradiation and, occasionally, surgery in subsequently involved areas. There were trends for more frequent splenectomies in patients with Hodgkin's disease in whom zoster subsequently developed, and for more frequent corticosteroid therapy in patiens with disseminated zoster. Advanced stage of Hodgkin's disease, in itself, was not associated with development of zoster, and the onset of zoster did not herald a poor prognosis for the underlying disease. Herpes zoster was, thus, largely a source of increased morbidity rather than mortality in the population studied, and multiple factors appeared to predispose to the development of zoster in this group of patients.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 581329     DOI: 10.1016/0002-9343(78)90791-x

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  23 in total

1.  Dementia following herpes zoster encephalitis.

Authors:  Katherine J Bangen; Lisa Delano-Wood; Christina E Wierenga; Nikki H Stricker; John R Hesselink; Mark W Bondi
Journal:  Clin Neuropsychol       Date:  2010-05-24       Impact factor: 3.535

2.  Approches actuelles au traitement du zona: Aspects controversés du traitement du zona.

Authors:  R Bissonnette; G Leclerc
Journal:  Can Fam Physician       Date:  1992-04       Impact factor: 3.275

3.  Herpes zoster mistaken for biliary colic and treated by laparoscopic cholecystectomy: a cautionary case report.

Authors:  I Hassan; J H Donohue
Journal:  Surg Endosc       Date:  1996-08       Impact factor: 4.584

4.  Varicella-zoster virus proteins in skin lesions: implications for a novel role of ORF29p in chickenpox.

Authors:  P W Annunziato; O Lungu; C Panagiotidis; J H Zhang; D N Silvers; A A Gershon; S J Silverstein
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

5.  Varicella-zoster virus hepatitis and a suggested management plan for prevention of VZV infection in adult liver transplant recipients.

Authors:  S Kusne; O Pappo; R Manez; G Pazin; B Carpenter; J J Fung; T E Starzl
Journal:  Transplantation       Date:  1995-09-27       Impact factor: 4.939

6.  Hemidiaphragmatic paresis after cervical herpes zoster.

Authors:  L Derveaux; L M Lacquet
Journal:  Thorax       Date:  1982-11       Impact factor: 9.139

7.  Severe herpes zoster infection in the United Kingdom: experience in a regional infectious disease unit.

Authors:  P Bannister; B Crosse
Journal:  J R Soc Med       Date:  1989-03       Impact factor: 5.344

Review 8.  Antiviral therapy of acute herpes zoster in older patients.

Authors:  K Herne; R Cirelli; P Lee; S K Tyring
Journal:  Drugs Aging       Date:  1996-02       Impact factor: 3.923

9.  Undiagnosed diabetes mellitus in patients with Herpes Zoster.

Authors:  Mohammad Nassaji-Zavareh; Ramin Taheri; Raheb Ghorbani; Maryam Aminian
Journal:  Indian J Dermatol       Date:  2008       Impact factor: 1.494

10.  Incidence of herpes zoster ophthalmicus: results from the Pacific Ocular Inflammation Study.

Authors:  Durga S Borkar; Vivien M Tham; Elizabeth Esterberg; Kathryn J Ray; Aleli C Vinoya; John V Parker; Aileen Uchida; Nisha R Acharya
Journal:  Ophthalmology       Date:  2012-12-01       Impact factor: 12.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.